EUVIMEDEUVIMED entdecken
Crossref

Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway

Xiaoying Li, Li Zhou, Ruike Wang, Yangnan Zhang, Wei Li

Journal of Biochemical and Molecular Toxicology · 2023

DOI: 10.1002/jbt.23328 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2023. Verfasst von Xiaoying Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Deregulation of epidermal growth factor receptor (EGFR) signaling is frequently observed in non‐small cell lung cancer (NSCLC). The present study aimed to determine the impact of dihydromyricetin (DHM) on NSCLC, a natural compound extracted from Ampelopsis grossedentata with various pharmacological activities. Results of the present study demonstrated that DHM may act as a promising antitumor agent for NSCLC therapy, inhibiting the growth of cancer cells in vitro and in vivo. Mechanistically, results of the present study demonstrated that exposure to DHM downregulated the activity of wild‐type (WT) and mutant EGFRs (mutations, exon 19 deletion, and L858R/T790M mutation). Moreover, western blot analysis indicated that DHM induced cell apoptosis via suppression of the antiapoptotic protein, survivin. Results of the present study further demonstrated that depletion or activation of EGFR/Akt signaling may regulate survivin expression though modulating ubiquitination. Collectively, these results suggested that DHM may act as a potential EGFR inhibitor, and may provide a novel choice of treatment strategy for patients with NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansSurvivinErbB ReceptorsProto-Oncogene Proteins c-aktDown-RegulationCell Line, TumorProtein Kinase InhibitorsMutationSignal TransductionApoptosisFlavonols

Stichwörter der Autor:innen

dihydromyricetinepidermal growth factor receptornon-small-cell lung cancersurvivin

Substanzen

SurvivinErbB ReceptorsProto-Oncogene Proteins c-aktProtein Kinase InhibitorsdihydromyricetinFlavonolsEGFR protein, human

Autor:innen und Institutionen

  • Department of Radiology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
  • Department of Pathology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital of Central South University, Changsha, Hunan, China.
  • Cell Transplantation and Gene Therapy Institute, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Hunan Province

Zitieren

APA

Li, X., Zhou, L., Wang, R., Zhang, Y., & Li, W. (2023). Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.23328

Vancouver

Li X, Zhou L, Wang R, Zhang Y, Li W. Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway. Journal of Biochemical and Molecular Toxicology. 2023. doi:10.1002/jbt.23328

BibTeX
@article{Li2023,
  author = {Li, Xiaoying and Zhou, Li and Wang, Ruike and Zhang, Yangnan and Li, Wei},
  title = {Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway},
  journal = {Journal of Biochemical and Molecular Toxicology},
  year = {2023},
  doi = {10.1002/jbt.23328}
}
Kostenlos starten →